



Collaboration. Acceleration. Results.

Multiple Sclerosis Expert Dr. Alfred Sandrock from Biogen Idec Joins the Myelin Repair Foundation's Clinical Advisory Board

SARATOGA, Calif. – March 13, 2012 – The [Myelin Repair Foundation](#) (MRF), the only foundation focused on the discovery and development of [myelin repair](#) therapeutics for multiple sclerosis (MS), today announced the appointment of Dr. Alfred Sandrock to its [Clinical Advisory Board](#). As Senior Vice President, Development Sciences and Chief Medical Officer at [Biogen Idec](#) (NASDAQ: BIIB), Dr. Sandrock joins fellow MRF Clinical Advisory Board members to bring unparalleled MS expertise from both the biotechnology industry and academic research to the Myelin Repair Foundation.

“Biogen Idec has an unwavering commitment to innovative science that can improve the lives of people living with MS. We’re honored to support the work of organizations like the Myelin Repair Foundation who share this commitment.” said Dr. Sandrock. “Through MRF’s work, we hope to accelerate myelin discoveries and more quickly bring these important therapies to MS patients. I’m excited to join the MRF board and support this important work.”

Dr. Sandrock heads Biogen Idec’s efforts on all clinical development programs, including multiple sclerosis. At Biogen Idec, he worked on the clinical trials of [Avonex](#) and led the development of [Tysabri](#) for multiple sclerosis. Dr. Sandrock is a board-certified neurologist and is Assistant Clinical Professor of Neurology at Harvard Medical School. He received an M.D. from Harvard Medical School in Boston and a Ph.D. in Neurobiology from Harvard University in Cambridge. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology (electromyography) at Massachusetts General Hospital. Dr. Sandrock’s MS drug development expertise will offer valuable guidance in MRF’s efforts to accelerate scientific discoveries to commercialization through the [MRF translational medicine platform](#).

“The multiple sclerosis community holds the deepest respect for Dr. Sandrock’s invaluable contributions to developing MS therapeutics that already treat millions of patients,” said Scott Johnson, president of the Myelin Repair Foundation. “As a leader in demonstrating a critical new role for non-profits as a connector between academic researchers and pharmaceutical companies, the MRF is pleased that Dr. Sandrock will join our efforts to advance myelin repair therapeutics to reach MS patients soon.”

The Myelin Repair Foundation is a non-partisan, non-profit organization focused on shortening the time to market for the first myelin repair therapeutic for patients. Generously supported by philanthropic donations, the MRF’s goal is to initiate a myelin repair clinical trial Phase 1 by 2014.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) (<http://www.myelinrepair.org>) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. Its [Accelerated Research Collaboration™](#) (ARC™) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.

Contact:

Jennifer Chang at the Myelin Repair Foundation

jchang@myelinrepair.org

408-871-2410

###